<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates</h1>
  <ul>
<li>Merck Says Phase 2 Study of Potential Lung Cancer Drug Showed 'Clinically Meaningful' Response Rates Merck (MRK) said Sunday that results from its IDeate-Lung01 phase 2 trial evaluating ifinatamab deru Upgrade to read th</li>
<li>A Silver or Gold subscription plan is required to access premium news articles.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/merck-says-phase-2-study-093503293.html">Source</a> · 2025-09-08T09:35:03+00:00</p>
</body>
</html>